PlasmaTech Biopharmaceuticals Expands Rare Disease Pipeline With License Agreement for Gene Therapy in Fanconi Anemia & CRISPR/Cas9-Based Technology Platform for Rare Blood Disorders Print E-mail
Monday, 15 June 2015 08:10
NEW YORK, NY and CLEVELAND, OH--PlasmaTech Biopharmaceuticals, Inc. (NASDAQ: PTBI), a biopharmaceutical company focused on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases, announced today that it has added another adeno-associated virus (AAV) gene therapy program to its product pipeline. The Company has licensed an AAV gene therapy and IP from the University of Minnesota to treat patients with Fanconi anemia (FA) disorder and other rare blood diseases.
Read more...
 
PlasmaTech Biopharmaceuticals Announces License Agreement for AAV Gene Therapy to Treat Patients With Juvenile Batten Disease Print E-mail
Monday, 08 June 2015 09:13
 New York, NY (June 8, 2015) PlasmaTech Biopharmaceuticals, Inc. (NASDAQ: PTBI), a biopharmaceutical company focused on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases announced today that it has added another adeno-associated virus (AAV) gene therapy program to its product pipeline.
Read more...
 
Actinium's Clinical Data Generate Significant Interest at 2015 ASCO Annual Meeting Print E-mail
Thursday, 04 June 2015 12:39
NEW YORK, NY--Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced that the presentation of poster and abstract at ASCO 2015, the 51stAnnual Meeting of American Society of Clinical Oncology, was given in Chicago on May 31.
Read more...
 
Pluristem Awarded Grant from Israel’s Ministry of Economy for Marketing its PLX Cell Therapy in Japan Print E-mail
Wednesday, 03 June 2015 19:22
HAIFA, ISRAEL--Pluristem Therapeutics Inc. (NasdaqCM: PSTI), a leading developer of placenta-based cell therapy products, today announced that it has been awarded a Smart Money grant from Israel’s Ministry of Economy.
Read more...
 
Pluristem Granted Key Cell Patents in Asia, Russia, Mexico, and Israel Print E-mail
Monday, 01 June 2015 14:36
Haifa, Israel, June 1, 2015 -- Pluristem Therapeutics, a leading developer of placenta-based cell therapy products, today announced it has been granted patents covering cell manufacturing, pharmaceutical compositions and disease treatment in China, South Korea, Mexico, Russia, and Israel.
Read more...
 
Pluristem Granted Key Cell Patents in Asia, Russia, Mexico, and Israel Print E-mail
Monday, 01 June 2015 14:36
Haifa, Israel, June 1, 2015 -- Pluristem Therapeutics, a leading developer of placenta-based cell therapy products, today announced it has been granted patents covering cell manufacturing, pharmaceutical compositions and disease treatment in China, South Korea, Mexico, Russia, and Israel.
Read more...
 
Actinium’s Actimab-A High Response Rates Presented at 2015 ASCO Annual Meeting Clinical Advisory Board Chairman Dr. Joseph Jurcic Presents Data from Ongoing Actimab-A Phase I/II Clinical Trial Print E-mail
Friday, 29 May 2015 18:34
NEW YORK, NY –- Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced its poster and abstract at ASCO 2015, the 51st Annual Meeting of American Society of Clinical Oncology, held in Chicago on May 29 – June 2. Data will be presented from the Company’s ongoing multi-center Phase 1/2 Study for Actimab-A for the treatment of newly diagnosed Acute Myeloid Leukemia (AML) in elderly patients.
Read more...
 
Provectus’ Abstract on Liver Cancer Accepted for Poster Presentation at 6th Asia-Pacific Primary Liver Cancer Expert Meeting Print E-mail
Thursday, 28 May 2015 19:27
KNOXVILLE, Tenn.--Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT), a clinical-stage oncology and dermatology biopharmaceutical company (“Provectus” or the “Company”), announced today that the organizing committee of the 6th Asia-Pacific Primary Liver Cancer Expert Meeting has accepted the Company’s abstract "Phase 1 Study of PV-10 for Chemoablation of Hepatocellular Cancer and Cancer Metastatic to the Liver", for a poster presentation.
Read more...
 
Provectus Biopharmaceuticals’s Abstract Accepted for Poster Presentation at 5th European Post-Chicago Melanoma / Skin Cancer Meeting Print E-mail
Wednesday, 27 May 2015 18:50
KNOXVILLE, Tenn.--Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT, http://www.pvct.com), a clinical-stage oncology and dermatology biopharmaceutical company (“Provectus” or the “Company”), today announced that the presentation committee of the 5th European Post-Chicago Melanoma / Skin Cancer Meeting has accepted its abstract titled “Trials in Progress: Intralesional Rose Bengal vs Systemic Chemotherapy for Treatment of Locally Advanced Cutaneous Melanoma.”
Read more...
 
PlasmaTech Biopharmaceuticals Announces Orphan Drug and Rare Pediatric Disease Designations from FDA Print E-mail
Wednesday, 20 May 2015 14:03
NEW YORK, NY--PlasmaTech Biopharmaceuticals, Inc. (PTBI), a biopharmaceutical company focused on gene therapy and plasma-based products for severe and life- threatening rare diseases announced today that the U.S. Food and Drug Administration (FDA) had granted both Orphan Drug Designation and Rare Pediatric Disease Designation for both of PlasmaTech Biopharmaceuticals' lead product candidates for the treatment of Sanfilippo Syndromes A and B.
Read more...
 
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>

Page 3 of 12

Newsletter